NR may just be a waste of money, safe but ineffective. NMN seems similarly useless in humans, but it may not even be safe.
Risks and Benefits of Nicotinamide Mononucleotide (NMN), a NAD+ Booster
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
Both NR and NMN have been shown to have beneficial effects in rodents, though they haven’t been tested side by side. Both precursors raise blood levels of NAD+ in people, but similarly haven’t been pitted head to head against one another. One potential advantage of NMN over NR is that it may be more stable in the bloodstream. In mouse blood at least, within an hour most NR is converted into NAM, whereas NMN levels remain steady. You could also argue that NMN is better because it’s a direct precursor of NAD+, whereas NR first has to be converted to NMN. So, we might as well just take NMN in the first place. Ironically, the exact opposite argument can also be made, based on the inability of NMN to pass through cell membranes.
Structurally, NMN is just NR with a phosphate group attached to it. The phosphate charge prevents NMN from passing in and out of cells. So, to get inside a cell, NMN first has to be converted into NR. Then, once inside, the NR can turn back into NMN, and make NAD+.
So, if NMN first has to be converted into NR for cell entry, the argument goes, maybe you might as well just take NR to begin with, because there’s no NMN transporter. Or is there? An NMN transporter was recently described (at least in mouse intestine). So, maybe NMN is able to skip the NR step, and pass directly into cells to make NAD+ after all. However, the evidence that such a NMN transporter exists remains controversial.
NMN boasts a long list of rodent healthspan benefits, but, unlike NR, has yet to demonstrate an extension of mammalian lifespan. What about in people? There have just been a few human NMN studies published to date. One small study of healthy middle-aged men found that various single doses had no apparent effect on any of the measured variables, including retinal eye function, sleep quality, heart rate, blood pressure, oxygenation, or body temperature. A 12-week study of daily NMN supplementation in middle-aged men and women similarly found no significant effects on any outcome, including lean mass, muscle mass, body fat, blood sugars, cholesterol, or insulin sensitivity. NMN did boost blood NAD+ levels, though they peaked after the first month, and then trended down for months two and three. So, there may have been an adaptive drop in NAD+ synthesis, as was suspected with NR. Like NR, NMN also fails to raise NAD+ in muscle tissue.
One study, evocatively entitled “Nicotinamide Mononucleotide Supplementation Enhances Aerobic Capacity in Amateur Runners,” tested three different doses of NMN versus placebo for six weeks among young and middle-aged recreational runners. Aerobic capacity was increased at one ventilatory threshold, but not the other. No overall benefit for aerobic capacity or peak power, or any of another ten measures of cardiopulmonary function was found. If you measure enough things, statistical outliers, both positive and negative ones, can just pop up as flukes. For example, the researchers noted significant improvement in the single-leg stance test, but the NMN had no significant effect on any of the other physical function tests. And upon closer inspection, the apparent single-leg balance benefit was only found in the middle-dose group compared to the high-dose group, because the high-dose group ended up doing slightly worse compared to baseline. No significant effect was found for any of the doses compared to placebo.
A similar issue can be found in a 12-week study of NMN supplementation in older adults. The NMN company-funded authors concluded that NMN “improved lower limb function and reduced drowsiness in older adults.” But it failed to significantly affect 16 additional measures, including other tests of lower limb function and fatigue. There are so few NMN studies that this kind of shotgun approach is understandable, casting the widest possible net for effects to be further tested, but on their own cannot be presented as convincing proof of efficacy.
All of the above NMN studies were on healthy individuals. What about testing NMN on those who are already metabolically compromised? Overweight or obese postmenopausal women with prediabetes were randomized to NMN or placebo for 10 weeks. NMN didn’t seem to affect body weight or composition, liver fat, blood pressure, or a dozen other metabolic variables. But it did improve muscle insulin sensitivity, though not enough to affect insulin levels, or short- or long-term blood sugar control. This may be because insulin sensitivity in the liver and body fat remained unchanged. NMN also appeared to have no effect on mitochondrial function or muscle strength, fatigability, or recovery.
In terms of safety, NMN shills speak of it as being naturally found in fruits and vegetables. But even the most concentrated sources (edamame, avocado, and broccoli) have over a hundred times less per serving than the typical NMN supplement dose. The same could be said for NR in milk (human and otherwise).
There are safety evaluations for NMN on rats and dogs, but unlike NR, supplemental doses of NMN have yet to be shown as safe for human consumption. There are rodent studies showing that NMN may have negative metabolic consequences compared to placebo, but the most serious concern is nerve degeneration. The accumulation of NMN in nerve cells is toxic. Since NR is converted into NMN, this is a major concern for NR supplementation as well. The type of nerve damage, axon degeneration, is a major contributor to a variety of neurodegenerative disorders. Blocking an NMN-synthesizing enzyme appeared to help damaged neurons in vitro, protection that’s abolished by adding NMN back, and adding an enzyme that chews up NMN was also found to be protective, further supporting a theory of degenerative effects of accumulating NMN. However, clinical effects remain theoretical, as these adverse effects have only been demonstrated in fish, mice, and petri dishes.
Of course, NMN supplements may not even have NMN in the first place. ChromaDex, which sells the rival supplement Tru Niagen (a form of NR), claims to have tested the 22 NMN brands with the highest market share on Amazon, and found that most had virtually no NMN at all. Ironically, many of the apparently fake NMN products displayed “certificates of analysis,” and carried hundreds or thousands of positive reviews. Evidently, only three out of 22 were found to contain as much NMN as advertised on their label. Of course, ChromaDex isn’t above being shady itself; it’s been accused of making hyped false claims for Tru Niagen by both the FDA and the Better Business Bureau.
In short, NR has been demonstrated to be relatively safe but not effective, and neither safety nor efficacy has been established for NMN.
Please consider volunteering to help out on the site.
- Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513-528.
- Okabe K, Yaku K, Uchida Y, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Front Nutr. 2022;9:868640.
- Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12(12):e0186459.
- Ratajczak J, Joffraud M, Trammell SAJ, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun. 2016;7:13103.
- Soma M, Lalam SK. The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions. Mol Biol Rep. 2022;49(10):9737-9748.
- Poddar SK, Sifat AE, Haque S, Nahid NA, Chowdhury S, Mehedi I. Nicotinamide mononucleotide: exploration of diverse therapeutic applications of a potential molecule. Biomolecules. 2019;9(1):34.
- Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(1):47-57.
- Schmidt MS, Brenner C. Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(7):660-661.
- Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806.
- Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153-160.
- Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021;18(1):54.
- Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults: a randomized, double-blind placebo-controlled study. Nutrients. 2022;14(4):755.
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
- Abdellatif M, Baur JA. NAD+ metabolism and cardiometabolic health: the human evidence. Cardiovasc Res. 2021;117(9):e106-e109.
- Shade C. The science behind NMN-a stable, reliable NAD+activator and anti-aging molecule. Integr Med (Encinitas). 2020;19(1):12-14.
- Ummarino S, Mozzon M, Zamporlini F, et al. Simultaneous quantitation of nicotinamide riboside, nicotinamide mononucleotide and nicotinamide adenine dinucleotide in milk by a novel enzyme-coupled assay. Food Chem. 2017;221:161-168.
- Turner J, Licollari A, Mihalcea E, Tan A. Safety evaluation for restorin® NMN, a NAD+ precursor. Front Pharmacol. 2021;12:749727.
- You Y, Gao Y, Wang H, et al. Subacute toxicity study of nicotinamide mononucleotide via oral administration. Front Pharmacol. 2020;11:604404.
- Ramsey KM, Mills KF, Satoh A, Imai SI. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell. 2008;7(1):78-88.
- Li C, Wu LE. Risks and rewards of targeting NAD+ homeostasis in the brain. Mech Ageing Dev. 2021;198:111545.
- Braidy N, Liu Y. NAD+ therapy in age-related degenerative disorders: a benefit/risk analysis. Exp Gerontol. 2020;132:110831.
- Cohen MS. Axon degeneration: too much NMN is actually bad? Curr Biol. 2017;27(8):R310-R312.
- Di Stefano M, Nascimento-Ferreira I, Orsomando G, et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death Differ. 2015;22(5):731-742.
- Di Stefano M, Loreto A, Orsomando G, et al. NMN deamidase delays wallerian degeneration and rescues axonal defects caused by NMNat2 deficiency in vivo. Curr Biol. 2017;27(6):784-794.
- Quantitative analysis of twenty-two NMN consumer products. ChromaDex. Oct 2021.
- NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN). ConsumerLab. Nov 2021.
- WARNING LETTER. ChromaDex. MARCS-CMS 607692. US FDA. Nov 2020.
- ChromaDex, Inc. Discontinues Advertising Claims for Tru Niagen Dietary Supplement Following National Advertising Division Challenge. Better Business Bureau. Oct 2021.
Motion graphics by Avo Media
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
Both NR and NMN have been shown to have beneficial effects in rodents, though they haven’t been tested side by side. Both precursors raise blood levels of NAD+ in people, but similarly haven’t been pitted head to head against one another. One potential advantage of NMN over NR is that it may be more stable in the bloodstream. In mouse blood at least, within an hour most NR is converted into NAM, whereas NMN levels remain steady. You could also argue that NMN is better because it’s a direct precursor of NAD+, whereas NR first has to be converted to NMN. So, we might as well just take NMN in the first place. Ironically, the exact opposite argument can also be made, based on the inability of NMN to pass through cell membranes.
Structurally, NMN is just NR with a phosphate group attached to it. The phosphate charge prevents NMN from passing in and out of cells. So, to get inside a cell, NMN first has to be converted into NR. Then, once inside, the NR can turn back into NMN, and make NAD+.
So, if NMN first has to be converted into NR for cell entry, the argument goes, maybe you might as well just take NR to begin with, because there’s no NMN transporter. Or is there? An NMN transporter was recently described (at least in mouse intestine). So, maybe NMN is able to skip the NR step, and pass directly into cells to make NAD+ after all. However, the evidence that such a NMN transporter exists remains controversial.
NMN boasts a long list of rodent healthspan benefits, but, unlike NR, has yet to demonstrate an extension of mammalian lifespan. What about in people? There have just been a few human NMN studies published to date. One small study of healthy middle-aged men found that various single doses had no apparent effect on any of the measured variables, including retinal eye function, sleep quality, heart rate, blood pressure, oxygenation, or body temperature. A 12-week study of daily NMN supplementation in middle-aged men and women similarly found no significant effects on any outcome, including lean mass, muscle mass, body fat, blood sugars, cholesterol, or insulin sensitivity. NMN did boost blood NAD+ levels, though they peaked after the first month, and then trended down for months two and three. So, there may have been an adaptive drop in NAD+ synthesis, as was suspected with NR. Like NR, NMN also fails to raise NAD+ in muscle tissue.
One study, evocatively entitled “Nicotinamide Mononucleotide Supplementation Enhances Aerobic Capacity in Amateur Runners,” tested three different doses of NMN versus placebo for six weeks among young and middle-aged recreational runners. Aerobic capacity was increased at one ventilatory threshold, but not the other. No overall benefit for aerobic capacity or peak power, or any of another ten measures of cardiopulmonary function was found. If you measure enough things, statistical outliers, both positive and negative ones, can just pop up as flukes. For example, the researchers noted significant improvement in the single-leg stance test, but the NMN had no significant effect on any of the other physical function tests. And upon closer inspection, the apparent single-leg balance benefit was only found in the middle-dose group compared to the high-dose group, because the high-dose group ended up doing slightly worse compared to baseline. No significant effect was found for any of the doses compared to placebo.
A similar issue can be found in a 12-week study of NMN supplementation in older adults. The NMN company-funded authors concluded that NMN “improved lower limb function and reduced drowsiness in older adults.” But it failed to significantly affect 16 additional measures, including other tests of lower limb function and fatigue. There are so few NMN studies that this kind of shotgun approach is understandable, casting the widest possible net for effects to be further tested, but on their own cannot be presented as convincing proof of efficacy.
All of the above NMN studies were on healthy individuals. What about testing NMN on those who are already metabolically compromised? Overweight or obese postmenopausal women with prediabetes were randomized to NMN or placebo for 10 weeks. NMN didn’t seem to affect body weight or composition, liver fat, blood pressure, or a dozen other metabolic variables. But it did improve muscle insulin sensitivity, though not enough to affect insulin levels, or short- or long-term blood sugar control. This may be because insulin sensitivity in the liver and body fat remained unchanged. NMN also appeared to have no effect on mitochondrial function or muscle strength, fatigability, or recovery.
In terms of safety, NMN shills speak of it as being naturally found in fruits and vegetables. But even the most concentrated sources (edamame, avocado, and broccoli) have over a hundred times less per serving than the typical NMN supplement dose. The same could be said for NR in milk (human and otherwise).
There are safety evaluations for NMN on rats and dogs, but unlike NR, supplemental doses of NMN have yet to be shown as safe for human consumption. There are rodent studies showing that NMN may have negative metabolic consequences compared to placebo, but the most serious concern is nerve degeneration. The accumulation of NMN in nerve cells is toxic. Since NR is converted into NMN, this is a major concern for NR supplementation as well. The type of nerve damage, axon degeneration, is a major contributor to a variety of neurodegenerative disorders. Blocking an NMN-synthesizing enzyme appeared to help damaged neurons in vitro, protection that’s abolished by adding NMN back, and adding an enzyme that chews up NMN was also found to be protective, further supporting a theory of degenerative effects of accumulating NMN. However, clinical effects remain theoretical, as these adverse effects have only been demonstrated in fish, mice, and petri dishes.
Of course, NMN supplements may not even have NMN in the first place. ChromaDex, which sells the rival supplement Tru Niagen (a form of NR), claims to have tested the 22 NMN brands with the highest market share on Amazon, and found that most had virtually no NMN at all. Ironically, many of the apparently fake NMN products displayed “certificates of analysis,” and carried hundreds or thousands of positive reviews. Evidently, only three out of 22 were found to contain as much NMN as advertised on their label. Of course, ChromaDex isn’t above being shady itself; it’s been accused of making hyped false claims for Tru Niagen by both the FDA and the Better Business Bureau.
In short, NR has been demonstrated to be relatively safe but not effective, and neither safety nor efficacy has been established for NMN.
Please consider volunteering to help out on the site.
- Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513-528.
- Okabe K, Yaku K, Uchida Y, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Front Nutr. 2022;9:868640.
- Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12(12):e0186459.
- Ratajczak J, Joffraud M, Trammell SAJ, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun. 2016;7:13103.
- Soma M, Lalam SK. The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions. Mol Biol Rep. 2022;49(10):9737-9748.
- Poddar SK, Sifat AE, Haque S, Nahid NA, Chowdhury S, Mehedi I. Nicotinamide mononucleotide: exploration of diverse therapeutic applications of a potential molecule. Biomolecules. 2019;9(1):34.
- Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(1):47-57.
- Schmidt MS, Brenner C. Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(7):660-661.
- Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806.
- Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153-160.
- Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021;18(1):54.
- Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults: a randomized, double-blind placebo-controlled study. Nutrients. 2022;14(4):755.
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
- Abdellatif M, Baur JA. NAD+ metabolism and cardiometabolic health: the human evidence. Cardiovasc Res. 2021;117(9):e106-e109.
- Shade C. The science behind NMN-a stable, reliable NAD+activator and anti-aging molecule. Integr Med (Encinitas). 2020;19(1):12-14.
- Ummarino S, Mozzon M, Zamporlini F, et al. Simultaneous quantitation of nicotinamide riboside, nicotinamide mononucleotide and nicotinamide adenine dinucleotide in milk by a novel enzyme-coupled assay. Food Chem. 2017;221:161-168.
- Turner J, Licollari A, Mihalcea E, Tan A. Safety evaluation for restorin® NMN, a NAD+ precursor. Front Pharmacol. 2021;12:749727.
- You Y, Gao Y, Wang H, et al. Subacute toxicity study of nicotinamide mononucleotide via oral administration. Front Pharmacol. 2020;11:604404.
- Ramsey KM, Mills KF, Satoh A, Imai SI. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell. 2008;7(1):78-88.
- Li C, Wu LE. Risks and rewards of targeting NAD+ homeostasis in the brain. Mech Ageing Dev. 2021;198:111545.
- Braidy N, Liu Y. NAD+ therapy in age-related degenerative disorders: a benefit/risk analysis. Exp Gerontol. 2020;132:110831.
- Cohen MS. Axon degeneration: too much NMN is actually bad? Curr Biol. 2017;27(8):R310-R312.
- Di Stefano M, Nascimento-Ferreira I, Orsomando G, et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death Differ. 2015;22(5):731-742.
- Di Stefano M, Loreto A, Orsomando G, et al. NMN deamidase delays wallerian degeneration and rescues axonal defects caused by NMNat2 deficiency in vivo. Curr Biol. 2017;27(6):784-794.
- Quantitative analysis of twenty-two NMN consumer products. ChromaDex. Oct 2021.
- NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN). ConsumerLab. Nov 2021.
- WARNING LETTER. ChromaDex. MARCS-CMS 607692. US FDA. Nov 2020.
- ChromaDex, Inc. Discontinues Advertising Claims for Tru Niagen Dietary Supplement Following National Advertising Division Challenge. Better Business Bureau. Oct 2021.
Motion graphics by Avo Media
Republishing "Risks and Benefits of Nicotinamide Mononucleotide (NMN), a NAD+ Booster"
You may republish this material online or in print under our Creative Commons licence. You must attribute the article to NutritionFacts.org with a link back to our website in your republication.
If any changes are made to the original text or video, you must indicate, reasonably, what has changed about the article or video.
You may not use our material for commercial purposes.
You may not apply legal terms or technological measures that restrict others from doing anything permitted here.
If you have any questions, please Contact Us
Risks and Benefits of Nicotinamide Mononucleotide (NMN), a NAD+ Booster
LicenseCreative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Content URLDoctor's Note
This is the sixth video in my NAD+ series. Check out the previous ones:
- Do NAD+ Levels Decline with Age?
- Can NAD+ Boosters Increase Lifespan and Healthspan?
- Risks and Benefits of Nicotinic Acid (NA), a NAD+ Booster
- Risks and Benefits of Nicotinamide (NAM), a NAD+ Booster
- Risks and Benefits of Nicotinamide Riboside (NR), a NAD+ Booster
Stay tuned for:
- Lesser-Known NAD+ Boosting Supplements—Tryptophan, NADH, NMNH, and NRH
- Risks of NAD+ Boosting Supplements
- Which NAD+ Booster Is Best?
- The Third Way to Boost NAD+
For more on aging, go to your local public library and check out my longevity book, How Not to Age, available in print, e-book, and audio. (All proceeds I receive from the book are donated directly to charity.)
If you haven't yet, you can subscribe to our free newsletter. With your subscription, you'll also get notifications for just-released blogs and videos. Check out our information page about our translated resources.